Annalee Armstrong headshot

Annalee Armstrong

Senior Editor

Annalee Armstrong is an award-winning biopharma journalist covering the business of drug development. She has been a journalist for more than 18 years, covering the pharmaceutical and biotech industry for the last eight.

Annalee began her career at small newspapers across Western Canada. During the assignment of a lifetime, the Yukon Quest Sled Dog Race, she met her husband in Alaska and eventually moved to the U.S. Since then, Annalee has covered energy, environmental regulations, healthcare and biopharma. Prior to BioSpace, Annalee was senior editor for Fierce Biotech, where she received several awards for her writing and editing. She lives in Ottawa, Ontario, with her husband, two wild boys, an anxious Rhodesian Ridgeback and an indifferent tabby cat.

She is senior editor at BioSpace and curates the Biopharm Executive newsletter every Wednesday. You can reach her at  annalee.armstrong@biospace.com. Follow her on LinkedIn.

Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.
The new policy signals an escalation by the Chinese government on biopharma deals but is unlikely to have a major impact given that the vast majority of foreign interest in Chinese biotech comes in the form of licensing agreements.
Estuary Biotherapeutics is seeking to address the root cause of autosomal dominant polycystic kidney disease with two gene therapy programs based on science from Yale.
AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in transthyretin-mediated amyloid cardiomyopathy.
In this webinar, BioSpace will gathered experts to discuss China’s impact on the future of biotech and how both U.S. and Chinese companies can thrive—and maybe even collaborate.
A new biotech co-founded by Paul Stoffels has formed to take on the CAR T cell assets of Galapagos almost a year after the company—now known as Lakefront Biotherapeutics—abandoned them.
The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors.
Since his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and Cassava, the FTC alleges.
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.
While innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.
Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.
For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.
The Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?
VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a market worth $8 billion.